{
  "component_scores": {
    "joint_involvement": {
      "score": 5,
      "justification": "Patient mentions polyarthrite rhumatoïde and multiple joint involvement (polyarticular). Additionally, patient is on biologic DMARD tocilizumab which indicates a clear clinical picture of established RA."
    },
    "serology": {
      "score": 3,
      "justification": "High-positive RF (value: positive) as mentioned in the facts. This corresponds to Category B scoring where High-positive RF OR high-positive ACPA (>3× ULN)."
    },
    "acute_phase": {
      "score": 1,
      "justification": "CRP value is unknown and not provided, so it cannot be scored here. However, the patient is on a biologic DMARD (tocilizumab), which suggests an active inflammatory phase."
    },
    "duration": {
      "score": 0,
      "justification": "Chronic/long-standing RA is not explicitly mentioned in the facts, but the presence of tocilizumab indicates a chronic condition. The patient's status as on DMARDs (methotrexate) also supports this."
    }
  },
  "acr_eular_total": 9,
  "treatment_context": {
    "has_dmard": true,
    "treatment_strength": "strong",
    "justification": "The patient is on biologic DMARD tocilizumab, which provides very strong evidence for established RA. Additionally, the patient is also taking a conventional synthetic DMARD (methotrexate), further supporting the classification."
  },
  "final_label": "RA+",
  "classification_rationale": "Based on the high serological markers of RF and the clinical picture involving multiple joints, and considering the treatment with biologic DMARD tocilizumab, the patient meets criteria for a definite rheumatoid arthritis diagnosis (RA+). The strong evidence from the combination of elevated RF/ACPA levels and established use of biologics supports this classification.",
  "confidence": "high",
  "patient_id": "0002",
  "agent": "Agent2_LLM_Reasoning_BALANCED",
  "retrieved_guidelines": [
    {
      "title": "Clinical Context",
      "content": "Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "text": "Clinical Context Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "relevance_score": 4.683000883810066
    },
    {
      "title": "Category B: Serology (0-3 points)",
      "content": "- Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "text": "Category B: Serology (0-3 points) - Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "relevance_score": 3.7519987234196357
    },
    {
      "title": "Category A: Joint Involvement (0-5 points)",
      "content": "- 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "text": "Category A: Joint Involvement (0-5 points) - 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "relevance_score": 2.188326647736484
    }
  ],
  "guideline_citation": "Aletaha D, et al. Arthritis Rheum. 2010;62(9):2569-2581",
  "evidence_trace": [
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "007",
      "snippet": "Diagnostic : polyarthrite rhumatoïde confirmée."
    },
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "007",
      "snippet": "Diagnostic : polyarthrite rhumatoïde confirmée."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0003",
      "line_no": 1,
      "snippet": "Antécédents : diabète de type 2 sous metformine 1 g/j, dyslipidémie. Mère atteinte de polyarthrite r"
    },
    {
      "type": "disease_mention",
      "stay_id": "S0003",
      "line_no": 7,
      "snippet": "Diagnostic : polyarthrite rhumatoïde confirmée."
    },
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "001",
      "snippet": "Antécédents : polyarthrite rhumatoïde depuis 2019, traitée par tocilizumab 162 mg toutes les 4 semai"
    },
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "001",
      "snippet": "Antécédents : polyarthrite rhumatoïde depuis 2019, traitée par tocilizumab 162 mg toutes les 4 semai"
    },
    {
      "type": "disease_mention",
      "stay_id": "",
      "line_no": "001",
      "snippet": "Antécédents : polyarthrite rhumatoïde depuis 2019, traitée par tocilizumab 162 mg toutes les 4 semai"
    },
    {
      "type": "disease_mention",
      "stay_id": "S0004",
      "line_no": 0,
      "snippet": "Hospitalisation pour syndrome infectieux : fièvre à 39,1°C, douleurs thoraciques, toux sèche depuis "
    },
    {
      "type": "lab",
      "test": "RF",
      "stay_id": "",
      "line_no": "004",
      "snippet": "RF : positif à 120 UI/mL."
    },
    {
      "type": "lab",
      "test": "anti-CCP",
      "stay_id": "",
      "line_no": "005",
      "snippet": "anti-CCP : positif à 48 U/mL."
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": "",
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 45 mg/L, VHS 60 mm/h, NFS normale."
    },
    {
      "type": "lab",
      "test": "RF",
      "stay_id": "",
      "line_no": "001",
      "snippet": "Antécédents : polyarthrite rhumatoïde depuis 2019, traitée par tocilizumab 162 mg toutes les 4 semai"
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": "",
      "line_no": "002",
      "snippet": "Laboratoire (J1) : CRP 150 mg/L, leucocytes 18,5 G/L, lymphocytes 0,8 G/L."
    },
    {
      "type": "drug",
      "name": "methotrexate",
      "stay_id": "",
      "line_no": "008",
      "snippet": "Prise en charge : début de méthotrexate 10 mg/semaine, avec acide folique 5 mg/j."
    },
    {
      "type": "drug",
      "name": "acide folique",
      "stay_id": "",
      "line_no": "008",
      "snippet": "Prise en charge : début de méthotrexate 10 mg/semaine, avec acide folique 5 mg/j."
    },
    {
      "type": "drug",
      "name": "tocilizumab",
      "stay_id": "",
      "line_no": "001",
      "snippet": "Antécédents : polyarthrite rhumatoïde depuis 2019, traitée par tocilizumab 162 mg toutes les 4 semai"
    },
    {
      "type": "drug",
      "name": "amphotéricine B liposomale",
      "stay_id": "",
      "line_no": "005",
      "snippet": "Diagnostic : aspergillose invasive."
    },
    {
      "type": "drug",
      "name": "tocilizumab",
      "stay_id": "",
      "line_no": "007",
      "snippet": "Prise en charge : amphotéricine B liposomale, arrêt définitif du tocilizumab."
    }
  ]
}